Wholesaler AmerisourceBergen and competitor McKesson report earnings; Merck expands work with Synthace;

> London-based Synthace said it has expanded an agreement to work with Merck & Co. ($MRK) on processes to use Synthace's bioprocesses and computer language Antha on a biomanufacturing platform for a number of undisclosed Merck molecules. Release

> Drug wholesaler AmerisourceBergen ($ABC) reported adjusted earnings of $1.17 per share for its fourth quarter, missing Wall Street projections of $1.18 per share. Report

> Drug wholesaling and services company McKesson ($MCK) reported adjusted earnings of $3.31 per share, well above analyst expectations of $2.97 per share. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.